First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses

Table 2 Characteristics of the study subjects

Study group	Subject ID	Age/sex/race	Infected HIV-1 subtype	Days of cART prior to entry	CD3 +/CD4 + level at entry (cells/µl)	Plasma HIV-1 RNA level at entry (copies/ml)
SAV001	2001004	43/male/black	B	537	1826	<2.00E+1
	1001005	37/male/white	ND	443	570	<2.00E+1
	2001008	40/male/white	B	1380	830	<2.00E+1
	2001009	28/male/white	A	960	500	<2.00E+1^d
	2001012	27/male/white	B	1832	598	<2.00E+1
	3001015	35/male/white	B	1185^c	694	2.50E+1
	3001018	44/male/white	B	1430	804	<2.00E+1
	2001022	30/male/white	B	229	419	<2.00E+1
	3001024	50/male/white	B	1097	486	2.22E+1
	1001025	44/female/white	B	2478	574	<2.00E+1
	4001029	30/male/black	B	445	491	<2.00E+1
	3001032	46/female/other^a	ND	1885^c	440	<2.00E+1
	3001033	45/male/white	B	395^c	515	<2.00E+1
Placebo	2001002	25/male/white	B	1011	702	<2.00E+1
	2001013	46/male/white	ND	573	618	<2.00E+1
	1001020	48/male/white	B	1843	754	<2.00E+1
	3001027	25/male/white	B	265	366	<2.00E+1
SAV001 + adjuvant	1001001	46/male/white	B	1269	539	<2.00E+1
	1001003	49/male/white	A	1289	833	<2.00E+1
	2001006	21/male/white	B	333	581	<2.00E+1
	2001010	46/male/white	B	4745^c	739	<2.00E+1
	2001011	33/female/black	B	1559	369	<2.00E+1
	3001016	48/male/white	B	730^c	626	<2.00E+1
	3001017	43/male/white	B	1550	459	<2.00E+1
	3001019	35/male/Asian	A	2220^c	555	<2.00E+1
	2001021	49/male/white	B	1848	1079	<2.00E+1
	3001026	29/male/white	C	252	485	<2.00E+1
	4001028	41/male/black	A	637	449	<2.00E+1
	4001031	40/male/white	ND	1290	794	<2.00E+1
Placebo +adjuv.	1001014	47/male/white	B	970^c	827	<2.00E+1
	2001007	48/male/asian	D	638	498	<2.00E+1
	1001023	49/male/white	B	1316	1057	<2.00E+1
	4001030	25/female/other^b	B	448	519	<2.00E+1

ISSN: 1742-4690